Andere Sprachen Ayala Pharmaceuticals, Inc.

Aktien

A3DMBH

US0076244062

ADXS

Markt geschlossen - OTC Markets Andere Börsenplätze 18:31:24 21.06.2024			% 5 Tage	% 1. Jan.
0,2625 ^USD	0,00 %		+0,57 %	-60,64 %

16.04.	Ayala Pharmaceuticals, Inc. meldet Ergebnis für das am 31. Dezember 2023 endende Geschäftsjahr	CI
16.04.	Ayala Pharmaceuticals, Inc. meldet Ergebnis für das am 31. Dezember 2023 endende Geschäftsjahr	CI

Andere Sprachen

Schalten Sie alle Nachrichten frei: Seien Sie als Erster informiert und reagieren Sie vor den Märkten!

100% kostenlose Registrierung

Ayala Pharmaceuticals Files Form 15 to Voluntarily Deregister and Suspend its Reporting Obligations	09.05.
Ayala Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	16.04.
Ayala Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	16.04.
North American Morning Briefing : Stock Futures Edge Lower Ahead of PPI Inflation Gauge	11.04.
North American Morning Briefing : Focus Turns to -2-	04.04.
Ayala Pharmaceuticals, Inc. Announces Departure of Roy Golan as Chief Financial Officer, Effective from June 25, 2024	03.04.
Andres Guttierez, Chief Medical Officer and Executive Vice President, Departs from Ayala Pharmaceuticals, Inc	03.04.
North American Morning Briefing : Stocks Set for -2-	28.03.
Ayala Pharmaceuticals Announces Completion of Sale of AL102 to Immunome	26.03.
Immunome, Inc. completed the acquisition of Assets from Ayala Pharmaceuticals, Inc..	25.03.
North American Morning Briefing : Fed's Preferred -2-	29.02.
North American Morning Briefing : Nvidia Ignites -2-	22.02.
Ayala Pharmaceuticals Announces Completion of Enrollment in Phase 3 RINGSIDE Study Evaluating AL102 in Desmoid Tumors	20.02.
Ayala Pharmaceuticals, Inc. Announces Completion of Enrollment in Phase 3 Ringside Study Evaluating AL102 in Desmoid Tumors	20.02.
Sector Update: Health Care Stocks Gain Late Afternoon	06.02.
Top Midday Gainers	06.02.
Immunome to Acquire Potential Desmoid Tumor Treatment From Ayala Pharmaceuticals; Shares Climb	06.02.
Immunome To Acquire AL102, A Phase 3 Asset for the Treatment of Desmoid Tumors, From Ayala Pharmaceuticals	06.02.
Immunome, Inc. entered into a definitive asset purchase agreement to acquire Assets from Ayala Pharmaceuticals, Inc. for $94.2 million.	06.02.
North American Morning Briefing : Stock Futures -2-	27.11.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Ayala Pharmaceuticals, Inc.

Aktien

A3DMBH

US0076244062

ADXS

Andere Sprachen

Filter